Candida spp. are the most common fungal pathogens responsible for invasive diseases in humans. Among them, Candida albicans is in general responsible for more than half of all Candida infections. However, recent studies showed a remarkable shift from C.albicans to non-albicans Candida species (NAC) at least in a number of centres. Candida krusei is known to be intrinsically resistant to fluconazole. Moreover, a decreased susceptibility to fluconazole among other NAC, especially for Candida glabrata has been reported. The changing epidemiology of candidemia and antifungal susceptibility data have an impact on the preferred empirical antifungal regimen. This study was undertaken to (i) state the ranking of Candida isolates among all positive blood cultures in our centre; ii) define the species distribution of Candida strains responsible for bloodstream infections and explore whether there is any potential increase in non-albicans Candida as compared to C. albicans; and to (iii) determine the influence of currently approved CLSI breakpoints on interpretation of antifungal susceptibility test (AST) results.
Full conference title:
22nd European Congress of Clinical Microbiology and Infectious Diseases
- ECCMID 22nd (2012)